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Background Transcatheter mitral valve replacement (TMVR) may be a valuable treatment option for mitral annular calcification
and severe mitral stenosis (MS) in patients at high operative risk. Pre-procedural virtual and printed simulations
may aid in procedure planning, device sizing, and mitigate complications such as valve embolization or left ventricu-
lar outflow tract (LVOT) obstruction.
...................................................................................................................................................................................................
Case summary We describe a case of TMVR in which multi-detector computed tomography (MDCT) derived, three-dimensional
virtual planning and a 3D-printed model of the patients’ left heart provided enhanced understanding of an individual
patient’s unique anatomy to determine feasibility, device sizing, and risk stratification. This resulted in deployment
of an adequately sized valve. Post-TMVR LVOT obstruction was treated with LVOT balloon dilatation and
percutaneous transluminal septal myocardial ablation.
...................................................................................................................................................................................................
Discussion Advanced MDCT-derived planning techniques introduce consistent 3D modeling and printing to enhance under-
standing of intracardiac anatomical relationships and test device implantation. Still, static measurements do not
feature haemodynamic factors, tissue, or device characteristics and do not predict device host interaction.
Transcatheter mitral valve replacement is feasible in MS when adequately pre-procedurally planned. Multi-detector
computed tomography-derived, 3D, virtual and printed models contribute to adequate planning in terms of deter-
mining patient eligibility, procedure feasibility, and device sizing. However, static 3D modeling cannot completely
eliminate the risk of peri-procedural complications.
                                                                                                                                                                                                                   
Keywords Transcatheter mitral valve replacement • Pre-procedural planning • 3D virtual models • Medical 3D
printing • Case report
* Corresponding author. Tel: þ31 (0)10 7035260, Email: n.vanmieghem@erasmusmc.nl
Handling Editor: Christoph Sinning
Peer-reviewers: Piotr Nikodem Rudzı´nski and Luigi Biasco
Compliance Editor: Anastasia Vamvakidou
Supplementary Material Editor: Ross Thomson
VC The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which
permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact
journals.permissions@oup.com
European Heart Journal - Case Reports (2020) 4, 1–6 CASE REPORT
doi:10.1093/ehjcr/ytaa098 Other
D
ow
nloaded from
 https://academ
ic.oup.com
/ehjcr/article/4/3/1/5835482 by Erasm
us U
niversity R
otterdam
 user on 23 Septem
ber 2020
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
Introduction
Patients with severe mitral annulus calcification (MAC) and stenosis
(MS) often have extensive comorbidities and are of high surgical risk.1
Transcatheter mitral valve replacement (TMVR) is a less invasive
treatment that precludes decalcification, instead, it exploits annular
calcium to facilitate valvular anchoring. However, it comes with add-
itional challenges2,3 making precise pre-procedural planning essential.
We describe a case of TMVR where advanced pre-procedural
planning with multi-detector computed tomography (MDCT) pro-
vides three-dimensional (3D) virtual modeling and 3D printing to en-
hance understanding of intracardiac anatomy, device sizing, and allow
implantation bench testing.
Timeline
Case presentation
A 65-year-old woman with a medical history of hypertension, dia-
betes, gout, morbid obesity (body mass index: 41.8 kg/m2), multiple
strokes, and coronary artery disease with prior stenting, presented
with recurrent acute pulmonary oedema [New York Heart
Association (NYHA) functional Class IV] despite optimal medical
treatment, among which: metoprolol (1  200 mg), intravenous fur-
osemide (2 80 mg), dapagliflozine (1 10 mg), and spironolactone
(1  25 mg). Physical examination showed peripheral oedema and
orthopnoea in a walking-aid dependent patient. Blood pressure was
138/79 mmHg with a heart rate of 56 b.p.m., a grade II/IV holodias-
tolic murmur was heard at the 3rd and 4th left intercostal space and
bilateral rales were heard upon auscultation of the lungs.
Transoesophageal echocardiography (TOE) revealed severe MAC
(Wilkins score 14) and MS (mean gradient 10 mmHg) combined with
secondary pulmonary hypertension (>60 mmHg). Basal septum wall
thickness was 14 mm with a left ventricular outflow tract (LVOT)
mean gradient (MG) of 14 mmHg. The multidisciplinary heart team
rejected the patient for surgery due to extensive comorbidities, hab-
itus, poor mobility, and mitral anatomical features and agreed with
TMVR. The Society of Thoracic Surgeons predicted risk of mortality
score was 5.6%, but further increased by morbid obesity, frailty, and
excessive MAC.
Multi-detector computed tomography-
derived 3D modeling
Double oblique MDCT analysis was used to appreciate the extent
and distribution of calcifications in the mitral annulus and measure
mitral orifice dimensions (Figure 1A–C). Based on these manual
measurements a 29 mm (outer diameter) Sapien3 (Edwards
Lifesciences Ltd, Irvine, CA, USA) transcatheter heart valve (THV)
seemed appropriate. A virtual 3D model was created using the
Materialise MimicsTM Enlight medical software package (Materialise,
Leuven, Belgium) (Figure 1D). The assessment was derived from the
mid-late diastolic phase. Based on the user’s input on the expected
landing zone, a best fit plane was obtained to determine minimal
and maximal diameters. Transcatheter heart valves of various sizes
and at various implantation depths were projected in this plane to
determine most suitable device size and estimate the neo-LVOT
for each scenario. A 26 mm Sapien3 was deemed the best fit
(Figure 2A) positioned 60% in the left atrium and 40% in the left
ventricle (Figure 2B and C).
An assessment in the late-systolic phase yielded an acceptable
neo-LVOT area of 212 mm2 (30% of original LVOT blocked)
(Figure 2C) which was notably higher than suggested cut-off values
(>170 mm2).4 Of note, virtual assessment of a Sapien3 29 mm at 60/
40 yielded a neo-LVOT of 150 mm2 (53% of original LVOT blocked).
A 3D-printed model (By Materialise, Leuven, Belgium) comple-
mented the virtual model and was used to implant an actual Sapien3
26 mm THV (Figure 3A–D) to confirm adequate valve apposition and
expansion visually. In this printed model, no evident LVOT obstruc-
tion was observed.
2016 Stroke and detection of moderate–severe mitral
stenosis (MS)
2017 Admission with acute pulmonary oedema with severe
pulmonary hypertension and severe MS. Denied
conventional mitral valve surgery based on
comorbidities
2018–2019 Recurrent admissions with acute pulmonary oedema
despite optimal medical therapy
September
2019
Heart team evaluation consensus for transcatheter
mitral valve replacement, creation of a multi-
detector computed tomography-derived
3D virtual model
October
2019
Percutaneous coronary intervention of the left
anterior descending artery and left circumflex
artery in work-up
October
2019
Transcatheter mitral valve replacement complicated
by left ventricular outflow tract obstruction which
required a percutaneous transluminal septal
myocardial ablation
Procedure
þ5 days
Discharge to rehabilitation
Learning points
• Transcatheter mitral valve replacement can be performed in
high-risk patients with severe mitral stenosis and mitral annular
calcification but requires advanced pre-procedural planning.
• Pre-procedural planning with multi-detector computed tomog-
raphy allows generation of three-dimensional virtual and
printed models to help define patient eligibility, procedure
feasibility, and device sizing.
• Static geometrical modeling cannot completely eliminate the
risk of peri-procedural complications since it does not inte-
grate haemodynamic and tissue-related factors.
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Figure 1 Multi-detector computed tomography mitral annulus measurement. (A and B) Multi-detector computed tomography image of the left
heart, the best fit plane through green line corresponds with the plane of image C (double oblique view). (C) Axial thin section of the mitral annulus.
The minimal and maximal diameter were 23.6 mm and 33.4 mm, respectively with an area of 632 mm2 measured manually (D) multi-detector com-
puted tomography-derived, three-dimensional virtual model of the left ventricle and aorta in mid-late diastolic phase. The annular calcium (orange)
was used to trace mitral annulus in 3D (green). The minimal and maximal mitral annulus diameters were 22.4 mm and 32.6 mm respectively, with an
annular area of 546 mm2.
Figure 2 Multi-detector computed tomography-derived 3D virtual model of the left heart with a prosthetic heart valve implanted. (A) Same model
as in Figure 1D with a cylinder positioned in the mitral annulus representing the dimensions of a 26 mm Sapien3 transcatheter heart valve. (B)
Overview of the left heart with the transcatheter heart valve implanted in mitral annulus, note the protrusion into the left ventricular outflow tract
forming a neo-left ventricular outflow tract (blue circle). (C) Automatically calculated, the minimal neo-left ventricular outflow tract area in late-sys-
tolic phase with an implanted transcatheter heart valve 60% in the left atrium, 40% in the left ventricle was 212 mm2 (30% of original left ventricular
outflow tract blocked).
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..Transcatheter mitral valve replacement
procedure
The procedure was performed under general anaesthesia and TOE
guidance and femoral access was obtained using a 16-Fr venous and
12-Fr arterial sheath. After transseptal puncture, septostomy was
performed with a 12 mm Admiral Xtreme balloon (Medtronic Inc.,
Minneapolis, MN, USA). A kissing balloon technique was applied that
included simultaneous inflation of an 18 mm True balloon (Bard
Vascular Inc., Tempe, AZ, USA) in the LVOT while implanting the
26 mm Sapien3 in MAC, aiming for a 60/40 position. The aim of this
technique was to preserve a minimum neo-LVOT dimension by piv-
oting the THV away from the LVOT (Figure 4A and B).
Transoesophageal echocardiography confirmed a trace residual para-
valvular mitral regurgitation (Figure 4C). The MG was 3 mmHg.
However, the neo-LVOT MG increased from 14 mmHg before to
34 mmHg after TMVR (Figure 4D). Balloon dilatation in the neo-
LVOT only mildly mitigated the gradient to 28 mmHg (Figure 4E).
Percutaneous transluminal septal myocardial ablation (PTSMA) with
2 ml of alcohol to the 1st septal perforator reduced the LVOT gradi-
ent to 20 mmHg, measured by transthoracic echocardiogram at
discharge (Figure 4F and G). Femoral venous and arterial access were
closed with suture based closure devices.
During the postoperative recovery, the patient developed a total
atrioventricular block and required a permanent pacemaker implant-
ation. The remainder of the hospital admission was uneventful and
the patient was discharged to a rehabilitation centre on postopera-
tive Day 5. Upon presentation at the outpatient clinic 1 month after
discharge, moderate dyspnoea was present (NYHA Class III). No re-
admission had occurred. Outpatient clinic MDCT evaluation showed
a systolic neo-LVOT of 120 mm2, with the THV implanted at a 45/55
position. Re-running the MDCT-derived 3D virtual model with a
26 mm Sapien3 at this implantation height revealed a projected neo-
LVOT of 177 mm2.
Discussion
Transcatheter mitral valve replacement is a viable treatment
for patients with severe MAC and MS at prohibitive operative
risk.2 However, anatomical factors such as location and extent of
annular calcification, shape and interaction with surrounding
Figure 3 Fitting a transcatheter mitral valve in a life-sized 3D-printed model of the patients’ left heart. Three-dimensional virtual model was 3D-
printed on a 1:1 scale. Calcium printed in blue. (A) Surgical view of the left atrium. A Sapien3 26 mm valve on its delivery system is positioned in the
mitral annulus. (B) The transcatheter heart valve after deployment in the mitral annulus, adequately fitted. (C) Transcatheter heart valve viewed from
the ventricular side. Pliers advanced from the aorta grasp the anterior mitral leaflet, the neo left ventricular outflow tract is highlighted in red. (D)
Transcatheter heart valve with deflected anterior mitral leaflet viewed from the aorta shows modest left ventricular outflow tract obstruction (high-
lighted in red). AML, anterior mitral leaflet; LA, left atrium; LAA, left atrial appendage; LSPV, left superior pulmonary vein; LVOT, left ventricular out-
flow tract.
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..structures pose a risk for serious complications such as valve
embolization, paravalvular leakage, or neo-LVOT obstruction.2
Multi-modality pre-procedural planning, is key to assess TMVR
eligibility.
Our case description illustrates the added value of MDCT-
derived 3D virtual and printed models to refine THV size selec-
tion and assure adequate anchoring. The use of a 3D software
package resulted in a 26 mm instead of a 29 mm Sapien THV. The
29 mm THV would arguably have resulted in a more dramatic
neo-LVOT obstruction. In spite of extensive neo-LVOT assess-
ment in both the virtual and 3D-printed model with estimated
neo-LVOT areas well over suggested cut-off values,4,5 the use of
the kissing balloon technique and neo-LVOT post-dilatation,
there was relevant neo-LVOT obstruction requiring PTSMA. This
characterizes the challenge of preventing neo-LVOT obstruction
in TMVR, where a tradeoff exists between adequate THV size
for anchoring and obstruction of the LVOT. Post-TMVR MDCT
analysis showed a smaller than anticipated in vivo neo-LVOT
with a THV positioned deeper into the left ventricle than pre-
procedurally planned. MDCT-derived 3D models provide a static
approximation of the contracting heart in which tissue and device
characteristics are currently not well integrated. The posterior
distribution of incompressible calcium as well as using a fixed
tubular structure to represent the THV may explain the discrep-
ancies found between the predicted and post-TMVR neo-LVOT.
Enriching virtual models with tissue and device characteristics as
well as haemodynamic factors might add value. Further assess-
ment of the neo-LVOT in a full cardiac cycle could provide more
insight in the risk for obstruction.
Conclusion
Transcatheter mitral valve replacement in MS is a challenging pro-
cedure which requires careful pre-procedural planning. Advanced
MDCT-derived planning techniques introduce consistent 3D
modeling and printing to enhance understanding of intra-cardiac
anatomical relationships and test device implantation. However,
as static geometrical 3D modeling does not incorporate haemo-
dynamic data and tissue or device characteristics, it cannot com-
pletely eliminate the risk of peri-procedural complications.
Therefore, pre-procedural planning of bail-out strategies remains
vital in TMVR.
Figure 4 Transcatheter mitral valve replacement overview. (A) Angiographic image of the unexpanded Sapien3 26 mm transcatheter heart valve
positioned in the mitral annulus. A guidewire with 18 mm non-compliant balloon is positioned in the left ventricular outflow tract, a temporary pace-
maker wire is placed in the right ventricle. (B) Deployment of the transcatheter heart valve in the mitral annulus with simultaneous inflation of the left
ventricular outflow tract balloon under rapid pacing. (C) Post-deployment transoesophageal echocardiography with colour Doppler showing mild
mitral regurgitation. (D) Pressure recordings of the left ventricle (blue line) and aorta (yellow line) showing a mean systolic gradient of 34 mmHg. (E)
Postdilatation of the left ventricular outflow tract with a 20 mm balloon resulting in a residual mean gradient of 28 mmHg. (F) Percutaneous translumi-
nal septal myocardial ablation in the first septal branch (red circle: 1.5 mm occlusion balloon in the septal perforator branch). (G) Discharge trans-
thoracic echocardiogram showing a residual mean gradient of 20 mmHg over the neo-left ventricular outflow tract. Of note, invasively and
transthoracic echocardiogram measured left ventricular outflow tract gradients are not directly comparable.
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